A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: Influence of valproic acid augmentation

Herbert Y. Meltzer, Stefania Bonaccorso, William V Bobo, Yuejin Chen, Karuna Jayathilake

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: Longitudinal data comparing the metabolic effects of olanzapine and risperidone with or without valproic acid supplementation in schizophrenic and bipolar patients are lacking. Method: This study compares the metabolic effects of olanzapine and risperidone in a prospective, randomized, open-label trial in 160 patients with DSM-IV-TR schizophrenia, schizoaffective disorder, or bipolar disorder after 1, 3, 6, and 12 months' treatment. The study was conducted between 2000 and 2006. The primary analysis compared all patients randomized to olanzapine or risperidone; the primary outcome measure was changes in triglycerides (TG), and TG/high density lipoprotein cholesterol (HDL-C) ratio, a risk factor for ischemic cardiovascular disease. Secondary analyses included the effect of concomitant valproic acid. Results: Significantly greater increases in weight (F4,434 = 4.7), body mass index (BMI) (F 4,424 = 5.1), glycosylated hemoglobin (HgbA1c) (F4,427 = 4.3), total cholesterol (F4,429 = 4.4), TG (F4,426 = 5.9), and TG/HDL-C ratio (F4,426 = 4.3) (P < .005 for all drug x time interaction effects) were observed at all but the initial time points in the olanzapine- compared to the risperidone patients. Olanzapine/+valproic acid produced significantly greater increases in HgbA1c, BMI, weight, TG, and TG/HDL-C than olanzapine/-valproic acid at 3 and 6 months, while risperidone/+valproic acid produced significantly smaller increases in HgbA1c, BMI, and weight at 1, 3, and 6 months than risperidone/-valproic acid. The olanzapine/+valproic acid group had significantly greater BMI, and weight at 1, 3, and 6 months, and greater HgbA1c at 3 and 6 months, compared with the risperidone/+valproic acid group. There were too few patients treated with mood stabilizers other than valproic acid to analyze effects of any other mood stabilizer separately. Metabolic effects did not differ significantly by diagnostic category (schizophrenia/schizoaffective disorder vs bipolar disorder). Conclusion: Further study of the metabolic effects of adjunctive valproic acid is indicated, as valproic acid may produce markedly different metabolic effects when combined with various antipsychotic drugs. Trial Registration: clinicaltrials.gov Identifier: NCT00179062.

Original languageEnglish (US)
Pages (from-to)1602-1610
Number of pages9
JournalJournal of Clinical Psychiatry
Volume72
Issue number12
DOIs
StatePublished - Dec 2011
Externally publishedYes

Fingerprint

olanzapine
Risperidone
Valproic Acid
Triglycerides
Body Mass Index
HDL Cholesterol
Weights and Measures
Bipolar Disorder
Psychotic Disorders
Schizophrenia
Augmentation

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Arts and Humanities (miscellaneous)

Cite this

A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients : Influence of valproic acid augmentation. / Meltzer, Herbert Y.; Bonaccorso, Stefania; Bobo, William V; Chen, Yuejin; Jayathilake, Karuna.

In: Journal of Clinical Psychiatry, Vol. 72, No. 12, 12.2011, p. 1602-1610.

Research output: Contribution to journalArticle

@article{1857c15548f44e7baff0319607e3e5a3,
title = "A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: Influence of valproic acid augmentation",
abstract = "Objective: Longitudinal data comparing the metabolic effects of olanzapine and risperidone with or without valproic acid supplementation in schizophrenic and bipolar patients are lacking. Method: This study compares the metabolic effects of olanzapine and risperidone in a prospective, randomized, open-label trial in 160 patients with DSM-IV-TR schizophrenia, schizoaffective disorder, or bipolar disorder after 1, 3, 6, and 12 months' treatment. The study was conducted between 2000 and 2006. The primary analysis compared all patients randomized to olanzapine or risperidone; the primary outcome measure was changes in triglycerides (TG), and TG/high density lipoprotein cholesterol (HDL-C) ratio, a risk factor for ischemic cardiovascular disease. Secondary analyses included the effect of concomitant valproic acid. Results: Significantly greater increases in weight (F4,434 = 4.7), body mass index (BMI) (F 4,424 = 5.1), glycosylated hemoglobin (HgbA1c) (F4,427 = 4.3), total cholesterol (F4,429 = 4.4), TG (F4,426 = 5.9), and TG/HDL-C ratio (F4,426 = 4.3) (P < .005 for all drug x time interaction effects) were observed at all but the initial time points in the olanzapine- compared to the risperidone patients. Olanzapine/+valproic acid produced significantly greater increases in HgbA1c, BMI, weight, TG, and TG/HDL-C than olanzapine/-valproic acid at 3 and 6 months, while risperidone/+valproic acid produced significantly smaller increases in HgbA1c, BMI, and weight at 1, 3, and 6 months than risperidone/-valproic acid. The olanzapine/+valproic acid group had significantly greater BMI, and weight at 1, 3, and 6 months, and greater HgbA1c at 3 and 6 months, compared with the risperidone/+valproic acid group. There were too few patients treated with mood stabilizers other than valproic acid to analyze effects of any other mood stabilizer separately. Metabolic effects did not differ significantly by diagnostic category (schizophrenia/schizoaffective disorder vs bipolar disorder). Conclusion: Further study of the metabolic effects of adjunctive valproic acid is indicated, as valproic acid may produce markedly different metabolic effects when combined with various antipsychotic drugs. Trial Registration: clinicaltrials.gov Identifier: NCT00179062.",
author = "Meltzer, {Herbert Y.} and Stefania Bonaccorso and Bobo, {William V} and Yuejin Chen and Karuna Jayathilake",
year = "2011",
month = "12",
doi = "10.4088/JCP.10m05997",
language = "English (US)",
volume = "72",
pages = "1602--1610",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "12",

}

TY - JOUR

T1 - A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients

T2 - Influence of valproic acid augmentation

AU - Meltzer, Herbert Y.

AU - Bonaccorso, Stefania

AU - Bobo, William V

AU - Chen, Yuejin

AU - Jayathilake, Karuna

PY - 2011/12

Y1 - 2011/12

N2 - Objective: Longitudinal data comparing the metabolic effects of olanzapine and risperidone with or without valproic acid supplementation in schizophrenic and bipolar patients are lacking. Method: This study compares the metabolic effects of olanzapine and risperidone in a prospective, randomized, open-label trial in 160 patients with DSM-IV-TR schizophrenia, schizoaffective disorder, or bipolar disorder after 1, 3, 6, and 12 months' treatment. The study was conducted between 2000 and 2006. The primary analysis compared all patients randomized to olanzapine or risperidone; the primary outcome measure was changes in triglycerides (TG), and TG/high density lipoprotein cholesterol (HDL-C) ratio, a risk factor for ischemic cardiovascular disease. Secondary analyses included the effect of concomitant valproic acid. Results: Significantly greater increases in weight (F4,434 = 4.7), body mass index (BMI) (F 4,424 = 5.1), glycosylated hemoglobin (HgbA1c) (F4,427 = 4.3), total cholesterol (F4,429 = 4.4), TG (F4,426 = 5.9), and TG/HDL-C ratio (F4,426 = 4.3) (P < .005 for all drug x time interaction effects) were observed at all but the initial time points in the olanzapine- compared to the risperidone patients. Olanzapine/+valproic acid produced significantly greater increases in HgbA1c, BMI, weight, TG, and TG/HDL-C than olanzapine/-valproic acid at 3 and 6 months, while risperidone/+valproic acid produced significantly smaller increases in HgbA1c, BMI, and weight at 1, 3, and 6 months than risperidone/-valproic acid. The olanzapine/+valproic acid group had significantly greater BMI, and weight at 1, 3, and 6 months, and greater HgbA1c at 3 and 6 months, compared with the risperidone/+valproic acid group. There were too few patients treated with mood stabilizers other than valproic acid to analyze effects of any other mood stabilizer separately. Metabolic effects did not differ significantly by diagnostic category (schizophrenia/schizoaffective disorder vs bipolar disorder). Conclusion: Further study of the metabolic effects of adjunctive valproic acid is indicated, as valproic acid may produce markedly different metabolic effects when combined with various antipsychotic drugs. Trial Registration: clinicaltrials.gov Identifier: NCT00179062.

AB - Objective: Longitudinal data comparing the metabolic effects of olanzapine and risperidone with or without valproic acid supplementation in schizophrenic and bipolar patients are lacking. Method: This study compares the metabolic effects of olanzapine and risperidone in a prospective, randomized, open-label trial in 160 patients with DSM-IV-TR schizophrenia, schizoaffective disorder, or bipolar disorder after 1, 3, 6, and 12 months' treatment. The study was conducted between 2000 and 2006. The primary analysis compared all patients randomized to olanzapine or risperidone; the primary outcome measure was changes in triglycerides (TG), and TG/high density lipoprotein cholesterol (HDL-C) ratio, a risk factor for ischemic cardiovascular disease. Secondary analyses included the effect of concomitant valproic acid. Results: Significantly greater increases in weight (F4,434 = 4.7), body mass index (BMI) (F 4,424 = 5.1), glycosylated hemoglobin (HgbA1c) (F4,427 = 4.3), total cholesterol (F4,429 = 4.4), TG (F4,426 = 5.9), and TG/HDL-C ratio (F4,426 = 4.3) (P < .005 for all drug x time interaction effects) were observed at all but the initial time points in the olanzapine- compared to the risperidone patients. Olanzapine/+valproic acid produced significantly greater increases in HgbA1c, BMI, weight, TG, and TG/HDL-C than olanzapine/-valproic acid at 3 and 6 months, while risperidone/+valproic acid produced significantly smaller increases in HgbA1c, BMI, and weight at 1, 3, and 6 months than risperidone/-valproic acid. The olanzapine/+valproic acid group had significantly greater BMI, and weight at 1, 3, and 6 months, and greater HgbA1c at 3 and 6 months, compared with the risperidone/+valproic acid group. There were too few patients treated with mood stabilizers other than valproic acid to analyze effects of any other mood stabilizer separately. Metabolic effects did not differ significantly by diagnostic category (schizophrenia/schizoaffective disorder vs bipolar disorder). Conclusion: Further study of the metabolic effects of adjunctive valproic acid is indicated, as valproic acid may produce markedly different metabolic effects when combined with various antipsychotic drugs. Trial Registration: clinicaltrials.gov Identifier: NCT00179062.

UR - http://www.scopus.com/inward/record.url?scp=84555169352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84555169352&partnerID=8YFLogxK

U2 - 10.4088/JCP.10m05997

DO - 10.4088/JCP.10m05997

M3 - Article

C2 - 21813074

AN - SCOPUS:84555169352

VL - 72

SP - 1602

EP - 1610

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 12

ER -